International Journal of Hematology and Oncology
2023, Vol 33, Num 4 (Special Issue) Page(s): 004-009
| Back | Table of Contents | Turkish Abstract | PDF | Mail to Author | |
Use of Second Generation Tyrosine Kinase Inhibitors for Second-Line Treatment of Chronic Myeloid Leukemia After Imatinib Failure
Yahya BUYUKASIK
Hacettepe University Faculty of Medicine, Department of Hematology, Ankara, TURKEY
Keywords: Chronic myeloid leukemia, Targeted therapy, Imatinib, Dasatinib, Nilotinib
Invention of imatinib was a great step for much more successful clinical management of chronic myeloid leukemia (CML). Now, two other tyrosine kinase inhibitors (TKIs) are available both for first-line and later treatments of CML. In Turkey, currently 2nd line TKIs are indicated only for imatinib failure. This review will evaluate indications for changing imatinib with dasatinib or nilotinib, success of the 2nd line agents in the second-line treatment and some important properties of these agents.
Yahya BUYUKASIK
Hacettepe University Faculty of Medicine, Department of Hematology, Ankara, TURKEY
Keywords: Chronic myeloid leukemia, Targeted therapy, Imatinib, Dasatinib, Nilotinib
Invention of imatinib was a great step for much more successful clinical management of chronic myeloid leukemia (CML). Now, two other tyrosine kinase inhibitors (TKIs) are available both for first-line and later treatments of CML. In Turkey, currently 2nd line TKIs are indicated only for imatinib failure. This review will evaluate indications for changing imatinib with dasatinib or nilotinib, success of the 2nd line agents in the second-line treatment and some important properties of these agents.
| Back | Table of Contents | Turkish Abstract | PDF | Mail to Author | |